Kidney Cancer Clinical Trial

Study of ARO-HIF2 in Patients With Advanced Clear Cell Renal Cell Carcinoma

Summary

The purpose of this study is to evaluate the safety and efficacy of ARO-HIF2 injection (also referred to as ARO-HIF2) and to determine the recommended Phase 2 dose in the treatment of patients with advanced clear cell renal cell carcinoma (ccRCC).

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Women of childbearing potential must have a negative pregnancy test, cannot be breastfeeding and must be willing to use contraception
Willing to provide written informed consent and to comply with study requirements
Histologically confirmed locally advanced or metastatic clear cell renal cell carcinoma that has progressed during or after at least two prior therapeutic regimens which must include vascular endothelial growth factor (VEGF)-targeted therapy and checkpoint inhibitor therapy or that has otherwise failed such therapies, is measurable disease per RECIST 1.1 criteria, is biopsy accessible
Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1
Estimated life expectancy of longer than 3 months
Adequate organ function at screening

Exclusion Criteria:

History of untreated brain metastasis or leptomeningeal disease or spinal cord compression
Failure to recover from reversible effects of prior anti-cancer therapy
Has received systemic therapy or radiation therapy within 2 weeks prior to first dose
History of solid organ or stem cell transplantation
Current use of anti-VEGF or mammalian target of rapamycin (mTOR) agents, or chronic immunosuppressive therapy
Any prior use of hypoxia inducible factor 2 (HIF2) inhibitors within 6 months prior to first dose
Current use of immune checkpoint inhibitors
Use of an investigational agent or device within 2 weeks prior to dosing, or current participation in an investigational study
Known HIV, hepatitis B or hepatitis C
History of other clinically meaningful disease
Major surgery within 4 weeks of Screening
Active malignancy requiring therapy other than ccRCC within 3 years of study entry

Note: Other eligibility criteria may apply per protocol.

Study is for people with:

Kidney Cancer

Phase:

Phase 1

Estimated Enrollment:

26

Study ID:

NCT04169711

Recruitment Status:

Completed

Sponsor:

Arrowhead Pharmaceuticals

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 5 Locations for this study

See Locations Near You

Research Site
Aurora Colorado, 80045, United States
Research Site
Las Vegas Nevada, 89169, United States
Research Site
Nashville Tennessee, 37232, United States
Research Site
Dallas Texas, 75390, United States
Research Site
Houston Texas, 77030, United States

How clear is this clinincal trial information?

Study is for people with:

Kidney Cancer

Phase:

Phase 1

Estimated Enrollment:

26

Study ID:

NCT04169711

Recruitment Status:

Completed

Sponsor:


Arrowhead Pharmaceuticals

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider